CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) announced today that Claes Glassell,
President and Chief Executive Officer, is scheduled to present a
corporate update at the 12th Annual BIO CEO and Investor Conference on
Tuesday, February 9th at 3:30 pm ET. The conference will be held at the
Waldorf-Astoria Hotel in New York City.
A live webcast of the presentation will be available from the Investor
Relations page of the Cerus web site at http://cerus2013.q4web.com.
A replay will be available for two weeks following the completion of the
event.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused on
commercializing the INTERCEPT Blood System to enhance blood safety. The
INTERCEPT Blood System is designed to inactivate blood-borne pathogens
in donated blood components intended for transfusion. Cerus currently
markets the INTERCEPT Blood System for both platelets and plasma in
Europe, Russia, the Middle East and selected countries in other regions
around the world. The INTERCEPT red blood cell system is currently in
clinical development. See http://www.cerus.com
for more information.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
Source: Cerus Corporation